Loading
Helminth Infection and Control · Journal article
Antibiotics · July 27, 2026
A consensus or society position rather than new primary data.
This is a narrative review examining novel antibiotics and non-traditional antimicrobial strategies (nanoparticles, antimicrobial peptides, bacteriophages, CRISPR/Cas, probiotics) for management of drug-resistant intra-abdominal infections. The source identifies emerging agents in clinical trials and alternative modalities at preclinical and early clinical stages, while highlighting translational barriers including delivery, safety, regulatory complexity, and the need for IAI-specific pharmacokinetic data.
Narrative review. Patients with drug-resistant intra-abdominal infections; review spans human, veterinary, agricultural, and environmental contexts per One Health principle.
New antibiotics in clinical trials include fluoroquinolones, beta-lactamase inhibitors, and polymyxin analogues Alternative strategies under exploration include nanoparticles, antimicrobial peptides, bacteriophages, CRISPR/Cas system, and probiotics Proposed mechanisms include multi-target membrane disruption, sequence-specific gene editing, and microbiome restoration
Key translational barriers identified: delivery challenges, safety concerns, regulatory complexity, and absence of IAI-specific pharmacokinetic data
Clinicians and researchers should recognize that management of drug-resistant IAIs is transitioning from monotherapy toward integrated multi-modal frameworks combining novel agents with rapid diagnostics and stewardship. However, most alternative modalities reviewed remain in preclinical or early clinical stages with significant translational barriers not yet overcome.
A narrative review synthesizing preclinical and clinical evidence on emerging therapeutic approaches for drug-resistant intra-abdominal infections, offering a translational perspective on alternative and novel strategies rather than reporting primary trial data.
As stated by the source record.
Clinicians and researchers should recognize that management of drug-resistant IAIs is transitioning from monotherapy toward integrated multi-modal frameworks combining novel agents with rapid diagnostics and stewardship. However, most alternative modalities reviewed remain in preclinical or early clinical stages with significant translational barriers not yet overcome.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no reported figures. That is a gap in the analysis, not a judgement about the study.
Antimicrobial resistance (AMR) among pathogens involved in intra-abdominal infections (IAIs) represents a critical and escalating clinical challenge. The interconnected nature of antimicrobial resistance, spanning human medicine, veterinary practice, agricultural use and environmental reservoirs, has required coordinated international responses based on the ‘One Health’ principle. This study presents an update on efforts underway worldwide to develop new antibiotics, novel combined antimicrobial agents, and alternatives to classic therapies for IAIs. New antibiotics or compounds with antibacterial activity are currently in various stages of clinical trials, including several fluoroquinolones, beta-lactamase inhibitors, and polymyxin analogues. To reduce the risk of bacterial resistance, various additions to antimicrobial treatments are being explored, such as nanoparticles (NPs), antimicrobial peptides (AMPs), bacteriophages, the CRISPR/Cas system, and probiotics. Each modality offers distinct mechanisms that circumvent established resistance pathways, including multi-target membrane disruption, sequence-specific gene editing, and microbiome restoration. Current preclinical and clinical evidence is synthesized, and key translational barriers, including delivery challenges, safety concerns, regulatory complexity, and the need for IAI-specific pharmacokinetic data are critically examined. In conclusion, the convergence of novel antibiotic agents and non-traditional antimicrobial strategies reviewed herein provides the foundation for a new paradigm in the management of drug-resistant IAIs. The transition from a monotherapy-centric approach to an integrated, multi-modal treatment framework, guided by rapid diagnostics and informed by antimicrobial stewardship, will be essential to preserve therapeutic efficacy against AMR threats of the coming decades.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.